Does Neuropathic Pain Affect the Quality of Sleep?

Melikoğlu, Meltem Alkan; Çelik, Ahmet

doi:10.5152/eurasianjmed.2017.16261

Cited by 20 publications

(21 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, using the PASI, which is currently accepted as the gold standard tool for evaluating disease severity in psoriasis, and using a validated sleep quality questionnaire, a significant negative correlation between psoriasis severity and sleep quality was determined in patients with psoriasis [8]. Sleep disturbances have also been detected in other chronic conditions [19].…”

Section: Discussionmentioning

confidence: 61%

Sleep Quality and its Association with Disease Severity in Psoriasis

Melikoğlu¹

2017

Eurasian J Med

View full text Add to dashboard Cite

Objective: The main purpose of this research was to crosscheck sleep quality in patients with psoriasis with that in healthy individuals and to evaluate a possible relationship between sleep quality and disease severity in these patients. Materials and Methods:Fifty-eight patients with plaque psoriasis and 58 age-and gender-matched healthy individuals were included. The Psoriasis Area and Severity Index (PASI) scoring method was used to assess the disease severity in patients with psoriasis. The sleep quality of the participants was evaluated by the Pittsburgh Sleep Quality Index (PSQI). The sleep quality scores of the patients with psoriasis were compared to those of healthy controls. Pearson' s correlation test and independent samples t-test and were used to interpret the data.Results: The mean disease duration was 11.1±7.4 years (mean±standard deviation), and the mean PASI was 14.1±5.3. In total, 60% of the patients with psoriasis (n=35) experienced poor sleep quality, and this frequency was considerably higher in the patients with psoriasis than in the healthy controls (p<0.000). Further, the mean PSQI in the patients with psoriasis (7.01±41.4) was higher than that in the healthy controls (4.18±2.76, p=0.000). The scores of daytime dysfunction, habitual sleep efficiency, and subjective sleep quality, which are the three components of sleep quality, were considerably higher in the patients with psoriasis than in the healthy controls (p=0.007, p=0.032, and p=0.034, respectively). Conclusion:Our results showing impaired sleep quality and its association with disease severity in patients with psoriasis may contribute to the management of psoriasis.Keywords: Psoriasis, sleep quality, psoriasis severity ÖZ Amaç: Sağlıklı kontrollerle, psöriazis hastalarında uyku kalitesini karşılaştırmak ve uyku kalitesi ve bu hastalarda hastalık şiddeti arasında olası bir ilişkiyi değerlendirmekti.Gereç ve Yöntem: Psöriazis hastalığı olan elli sekiz hasta yaş ve cinsiyet uyumlu 58 sağlıklı kontrol bu çalışmaya dahil edildi. Psöriazis alan ve şiddet indeksi (PASİ) hastalığın şiddetini değerlendirmek için kullanıldı. Katılımcıla-rın uyku kalitesi 'Pittsburgh uyku kalite indeksi' ile değerlendirildi. Psöriazis hastalığı olan hastaların uyku kalitesi puanları sağlıklı kontrol ile karşılaştırıldı. Bağımsız t testi ve Pearson korelasyon testi istatistiki değerlendirme için kullanıldı.Bulgular: Ortalama hastalık süresi 11,1±7,4 yıl (ortalama±standart sapma) ve ortalama PASI 14,1±5,3 olarak değerlendirildi. Psöriazis hastalarının %60'ında (n=35) uyku kalitesi düşüktü ve bu sıklık hastalarda sağlık-lı kontrollere göre anlamlı derecede yüksekti (p<0,000). Aynı zamanda hastalar için ortalama PSQI skoru (7,01±41,4) sağlıklı kontrollerden daha yüksekti (4,18±2,76; p=0,000). Uyku kalitesinin üç bileşeninin skorları; subjektif uyku kalitesi, alışılagelmiş uyku etkinliği ve günlük disfonksiyonu, psöriazisli hastalarda sağlıklı kontrollere göre anlamlı derecede yüksekti (sırasıyla p=0,034, p=0,032 ve p=0,007).Sonuç: Sonuç olarak, Psöriazi...

show abstract

Section: Discussionmentioning

confidence: 61%

Sleep Quality and its Association with Disease Severity in Psoriasis

Melikoğlu¹

2017

Eurasian J Med

View full text Add to dashboard Cite

show abstract

“…Neuropathic pain develops in 10–50% of patients with distal lower limb polyneuropathy in type 2 diabetes mellitus [ 15 , 16 , 17 ]. Almost all patients with diabetic neuropathic pain report quality of life impairment [ 18 ], with 80% experiencing poor sleep [ 19 , 20 , 21 ]. Unfortunately, drug therapy alone has not been effective enough in the treatment of many patients with severe neuropathic pain [ 18 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Experience of High Frequency and Low Frequency TENS in Treatment of Diabetic Neuropathic Pain in Russia

et al. 2022

View full text Add to dashboard Cite

Background: Transcutaneous electrical nerve stimulation (TENS) is presently one of the main methods of treatment for neuropathic pain in type II diabetes mellitus. The discussion about which TENS frequency is more effective in the treatment of neuropathic pain has been ongoing for many years. Despite this, the response of different aspects of neuropathic pain to various TENS modalities has not been sufficiently studied. Aim: To analyze changes in characteristics of neuropathic pain depending on the frequency of TENS. Materials and methods: Seventy-five Russian diabetic patients with painful distal axonal neuropathy were enrolled in the study. Patients were assigned to three groups: in the HF TENS group, 25 patients received standard drug therapy (Alpha-lipoic acid, Pentoxifylline, Vitamin B12, Gabapentin) + high-frequency TENS (HF); in the LF TENS group, 25 patients received standard drug therapy (Alpha-lipoic acid, Pentoxifylline, Vitamin B12, Gabapentin) + low-frequency TENS (LF); in the control group, 25 patients underwent just standard drug therapy (Alpha-lipoic acid, Pentoxifylline, Vitamin B12, Gabapentin). Pain intensity was calculated before and after treatment with visual analogue scale (VAS), McGill pain questionnaire (MPQ), Douleur Neuropathique 4 Questions (DN4) and Pain Drawing. Results: TENS increased the therapeutic effect of standard drug therapy, in the treatment of neuropathic pain, by 65.9% and prolonged its efficacy by 31% for up to 6 months after treatment. HF TENS had a more pronounced analgesic effect than LF TENS based on VAS (34.7%), sensory (57.6%) MPQ dimensions and DN4 (21%). Affective MPQ dimension with the use of LF TENS was lower than HF TENS by 34.7% immediately after treatment, by 47.3% after 2 months and by 34.8% after 6 months of the follow-up period. Conclusion: There are significant differences between HF and LF TENS based on pain assessment using various pain scales. This reflects the distinctive effects of different TENS modalities on different aspects of neuropathic pain.

show abstract

“…Recent evidence shows that there is a relation between sleep and NP. One recent study concluded that about 80% of patients suffering from NP have sleep disorders 10. It has also been reported that sleep deprivation can greatly reduce the pain thresholds along with signs of depression and anxiety which can aggravate pain 11.…”

Section: Introductionmentioning

confidence: 99%

<p>Melatonin MT2 receptor agonist IIK-7 produces antinociception by modulation of ROS and suppression of spinal microglial activation in neuropathic pain rats</p>

Kuthati

Davuluri

Yang

et al. 2019

JPR

View full text Add to dashboard Cite

Background In recent years, several melatonin (MLT) receptor agonists have been approved by FDA for the treatment of sleep disorders and depression. Very few studies have shed light on their efficacy against neuropathic pain (NP). IIK-7 is an MT-2 agonist known to promote sleep. Whether IIK-7 suppresses NP has not been reported, and the signaling profile is unknown. Objective To investigate the effect of melatonin type 2 receptor agonist IIK-7 on partial sciatic nerve transection-induced NP in rats and elucidate the underlying molecular mechanisms. Methods NP was induced by the PSNT in the left leg of adult male Wistar rats. On post-transection day 7, rats were implanted with intrathecal (i.t) catheter connected to an infusion pump and divided in to four groups: sham-operated/vehicle, PSNT/vehicle, PSNT/0.5 μg/hr IIK-7 and PSNT/0.5 μg IIK-7/1 μg 4-p/hr. To test the MT-2 dependence on IIK-7 activity, the animals were implanted with a single i.t catheter and injected MT-2 antagonist 4-Phenyl-2-propionamidotetralin (4-p) 20 mins prior to IIK-7 injection on day 7 after PSNT. The antinociceptive response was measured using a mechanical paw withdrawal threshold. Activation of microglial cells and the expression of NP-associated proteins in the spinal cord dorsal horn was assessed by immunofluorescence assay (IFA) and Western blotting (WB). Reactive oxygen species (ROS) scavenging ability of IIK-7 was evaluated by using bone marrow-derived macrophages (BMDM). Results Treatment with the MT-2 agonist IIK-7 significantly alleviated PSNT-induced mechanical allodynia and glial activation along with the inhibition of P44/42 MAPK, HMGB-1, STAT3, iNOS and casp-3 proteins. Conclusion IIK-7 attenuates NP through the suppression of glial activation and suppression of proteins involved in inflammation and apoptosis. MT-2 receptor agonists may establish a promising and unique therapeutic approach for the treatment of NP.

show abstract

Does Neuropathic Pain Affect the Quality of Sleep?

Cited by 20 publications

References 22 publications

Sleep Quality and its Association with Disease Severity in Psoriasis

Sleep Quality and its Association with Disease Severity in Psoriasis

Clinical Experience of High Frequency and Low Frequency TENS in Treatment of Diabetic Neuropathic Pain in Russia

<p>Melatonin MT2 receptor agonist IIK-7 produces antinociception by modulation of ROS and suppression of spinal microglial activation in neuropathic pain rats</p>

Contact Info

Product

Resources

About